Utility of Biomarkers in the Management of Inflammatory Bowel Disease

Overview

Journal Curr Treat Options Gastroenterol

Specialty Gastroenterology

Date 2017 Feb 1

PMID 28138859

Citations 3

Authors

Gursimran Kochhar

Bret Lashner

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is comprised of complex clinical and pathological conditions. It runs a chronic course, and proper management requires constant monitoring of disease activity. Recent evidence suggests that subjective patient scores have a poor correlation with disease activity. Endoscopy remains the gold standard for diagnosing and monitoring disease activity. As healthcare is moving towards less costly and less invasive treatments, the need for biomarkers in the management of IBD is evident. Over the last decade, several biomarkers have been found, which may correct the discrepancy between subjective patient scores and the need for endoscopy.

Citing Articles

Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease.

Farbod Y, Popov J, Armstrong D, Halder S, Marshall J, Tse F J Can Assoc Gastroenterol. 2022; 5(1):12-17.

PMID: 35118222 PMC: 8806041. DOI: 10.1093/jcag/gwab008.

Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease.

Waljee A, Wallace B, Cohen-Mekelburg S, Liu Y, Liu B, Sauder K JAMA Netw Open. 2019; 2(5):e193721.

PMID: 31074823 PMC: 6512283. DOI: 10.1001/jamanetworkopen.2019.3721.

Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.

Titz B, Gadaleta R, Lo Sasso G, Elamin A, Ekroos K, Ivanov N Int J Mol Sci. 2018; 19(9).

PMID: 30223557 PMC: 6163330. DOI: 10.3390/ijms19092775.

References

Darlington G, Wilson D, Lachman L . Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 1986; 103(3):787-93. PMC: 2114283. DOI: 10.1083/jcb.103.3.787. View

Lamb C, Mansfield J . Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2013; 2(1):13-18. PMC: 3724198. DOI: 10.1136/fg.2010.001362. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Cantorna M, Mahon B . Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004; 229(11):1136-42. DOI: 10.1177/153537020422901108. View

Jorgensen S, Agnholt J, Glerup H, Lyhne S, Villadsen G, Hvas C . Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010; 32(3):377-83. DOI: 10.1111/j.1365-2036.2010.04355.x. View

Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M . IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007; 13(12):1561-6. DOI: 10.1002/ibd.20226. View

Liu P, Stenger S, Li H, Wenzel L, Tan B, Krutzik S . Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768):1770-3. DOI: 10.1126/science.1123933. View

Schoepfer A, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D . Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19(2):332-41. DOI: 10.1097/MIB.0b013e3182810066. View

Sandborn W, Landers C, Tremaine W, Targan S . Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996; 71(5):431-6. DOI: 10.4065/71.5.431. View

10.

Kongsbak M, Levring T, Geisler C, von Essen M . The vitamin d receptor and T cell function. Front Immunol. 2013; 4:148. PMC: 3684798. DOI: 10.3389/fimmu.2013.00148. View

11.

Menees S, Powell C, Kurlander J, Goel A, Chey W . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015; 110(3):444-54. DOI: 10.1038/ajg.2015.6. View

12.

Yang Z, Clark N, Park K . Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol. 2013; 12(2):253-62.e2. PMC: 3865226. DOI: 10.1016/j.cgh.2013.06.028. View

13.

Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Farkkila M . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2007; 14(1):40-6. DOI: 10.1002/ibd.20312. View

14.

Arasaradnam R, Covington J, Nwokolo C . Editorial: Metabolomic analysis of breath volatile organic compounds--a new scent for inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 40(6):732-3. DOI: 10.1111/apt.12901. View

15.

Schoepfer A, Beglinger C, Straumann A, Trummler M, Vavricka S, Bruegger L . Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2009; 105(1):162-9. DOI: 10.1038/ajg.2009.545. View

16.

Lewis J . The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140(6):1817-1826.e2. PMC: 3749298. DOI: 10.1053/j.gastro.2010.11.058. View

17.

Liu W, Chen Y, Golan M, Annunziata M, Du J, Dougherty U . Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013; 123(9):3983-96. PMC: 3754241. DOI: 10.1172/JCI65842. View

18.

Meuwis M, Fillet M, Lutteri L, Maree R, Geurts P, de Seny D . Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008; 41(12):960-7. DOI: 10.1016/j.clinbiochem.2008.04.021. View

19.

Osterman M, Aberra F, Cross R, Liakos S, McCabe R, Shafran I . Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014; 12(11):1887-93.e3. PMC: 4214893. DOI: 10.1016/j.cgh.2014.03.035. View

20.

von Roon A, Karamountzos L, Purkayastha S, Reese G, Darzi A, Teare J . Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102(4):803-13. DOI: 10.1111/j.1572-0241.2007.01126.x. View